SpyGlass Pharma Inc. (SGP:NASDAQ) closed at $28.48 on October 23, 2026, up 0.92% on the day. The stock trades 12.2% below its 52-week high of $32.44 and 66.9% above its 52-week low of $17.06. Over the past year, it gained 7.9%. SpyGlass Pharma Inc. is part of the Health Care sector.
In 179 trading sessions since February 9, 2026, SGP closed higher on 93 days (52%). Its best day was April 13, 2026 (+15.04%) and its worst was July 1, 2026 (-12.53%). The stock moved 10% or more in a single session 7 times.
SpyGlass Pharma is a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company's mission is to significantly improve the lives of patients with chronic eye conditions by developing durable drug delivery solutions that can empower patients and surgeons with confidence in long-term disease control and vision preservation. The SpyGlass Pharma platform, a novel, non-bioerodible drug delivery technology, is designed to be used with various well-established, approved medicines, including bimatoprost and other small molecules, providing flexibility to potentially treat a range of conditions in the front and back of the eye. The company was founded in 2019 by Malik Y. Kahook, M.D. and Glenn Sussman to solve the lack of ophthalmic innovations that capitalize on durable treatment options.
Find more stocks like SGP with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.